West Pharmaceutical Services price to sales ratio WST

Market value divided by revenue over the last twelve months, since 2011.

Today, Oct 23, 2026: 8.3×
10-year median: 6.8×
Against its 10-year history: 67th; percentile: 0 is its lowest day, 100 its highest
10-year range: 3.7× to 13.6×
Peer median: 3.4×

West Pharmaceutical Services' price to sales ratio is 8.3× as of Oct 23, 2026.

That is above its ten-year median of 6.8×, higher than on 67% of days in the last ten years.

Over that time it ranged from 3.7× in Oct 2016 to 13.6× in Sep 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.4×.

Price to sales ratio over time

median 6.8×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	8.3×	5.5×	8.3×
2025	6.5×	5.0×	8.7×
2024	8.4×	7.2×	10.4×
2023	8.9×	5.9×	10.5×
2022	6.0×	5.5×	11.1×
2021	13.0×	9.1×	13.6×
2020	10.3×	5.2×	11.3×
2019	6.2×	4.3×	6.2×
2018	4.2×	3.9×	5.4×
2017	4.7×	3.8×	4.8×
2016	4.2×	2.8×	4.2×
2015	3.1×	2.5×	3.3×
2014	2.7×	2.0×	2.7×
2013	2.5×	1.5×	2.6×
2012	1.5×	1.1×	1.5×
2011	1.1×	1.0×	1.4×

Against its peers

Companies in Medical - Instruments & Supplies nearest West Pharmaceutical Services' size, closest first, today.

Company	Price to sales ratio
WSTWest Pharmaceutical Services	8.3×
RMDResMed	6.5×
MDLNMedline	n/m
SOLVSolventum	1.7×
BDXBecton, Dickinson and	2.6×
PENPenumbra	8.5×
COOCooper Companies	2.7×
ALGNAlign Technology	2.7×
GMEDGlobus Medical	3.5×
PODDInsulet	3.4×
MSAMSA Safety	3.6×
Peer median	3.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on West Pharmaceutical Services

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.